Reyon Pharmaceutical Co Ltd
102460
Company Profile
Business description
Reyon Pharmaceutical Co Ltd is a Korea-based pharmaceutical company. It is engaged in the manufacturing and distribution of specialty medicines and raw materials. The main business of the company has been divided into generic drugs, original drugs, and drug substances The key products include eye drops, injection, antibiotics, skeletal muscle relaxants, coagulation drugs, anti-inflammatory enzymes, and blood vessels dialectic drugs, among others.
Contact
416, Yeongdong-daero
8th floor, Gangnam-gu
Seoul
KORT: +82 234075222
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
445
Stocks News & Analysis
stocks
Navigating the ASX dividend landscape in 2026
Dividend yields are well below the 10-year average. Here’s how to navigate lower yields in 2026.
stocks
Meta stock has struggled amid AI spending concerns. Is it a buy?
Meta stock has lost ground as investors raise concern over capital expenditures and risky AI strategies.
stocks
Netflix Earnings: Strong, as expected; 2026 guidance confirms decelerating growth
We think Netflix stock is moderately overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,108.60 | 16.20 | 0.18% |
| CAC 40 | 8,079.50 | 16.92 | 0.21% |
| DAX 40 | 24,610.95 | 92.17 | -0.37% |
| Dow JONES (US) | 48,940.34 | 451.75 | 0.93% |
| FTSE 100 | 10,150.52 | 23.74 | 0.23% |
| HKSE | 26,585.06 | 97.55 | 0.37% |
| NASDAQ | 23,158.12 | 203.80 | 0.89% |
| Nikkei 225 | 52,774.64 | 216.46 | -0.41% |
| NZX 50 Index | 13,417.17 | 156.76 | -1.15% |
| S&P 500 | 6,857.11 | 60.25 | 0.89% |
| S&P/ASX 200 | 8,782.90 | 14.00 | 0.16% |
| SSE Composite Index | 4,116.94 | 3.29 | 0.08% |